Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 749

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 749
---
 |                   |   0.1 | ​ |      |  10.4 | ​ |
| Discount rate - operating leases                                        | ​ |                    |     — | % | ​    |  12.4 | % | ​                 |     — | % | ​    |  12.4 | % |

There are no other future minimum cash lease payments under the Assignment Agreements as of September 30, 2024. Future non-cash lease payments under the Assignment Agreements are$ 3,417, which are included within operating lease liability – current as of September 30, 2024. This non-cash lease payment is due at the end of the modified lease term, which is November 1, 2024.

F- 31

<div align='center'>CARA THERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(amounts in thousands, except share and per share data)

(unaudited)</div>

18. Related Party Transactions As of September 30, 2024, Vifor International owned 616,397 , or 13.5% , of the Company’s common stock. CSL Vifor and its affiliates are considered related parties as of September 30, 2024 and December 31, 2023 (see Note 12, Collaboration and Licensing Agreements ). As of September 30, 2024 and December 31, 2023, amounts due from CSL Vifor of $ 435 and $ 2,765 , respectively, primarily relating to royalty payments from CSL Vifor in the current period and the Company’s share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor, its commercial supply of KORSUVA injection to CSL Vifor, and royalty payments from CSL Vifor in the prior period were included within accounts receivable, net – related party. The Company’s collaborative revenue of $ 1,298 and $ 1,932 from its share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor was included within collaborative revenue for the three months ended September 30, 2024 and 2023, respectively. The Company’s collaborative revenue of $ 2,086 and $ 10,092 from its share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor was included